[
  {
    "ts": null,
    "headline": "Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates",
    "summary": "Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug’s commercial potentialIn September 2025, Sol-Gel announced Health Canada approval of EPSOLAYSol-Gel signed an additional agreement with Viatris covering Australia and New Zealand for both EPSOLAY and TWYNEO NESS ZIONA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering t",
    "url": "https://finnhub.io/api/news?id=53c7343f10bdd7751e17ec1568e2f4274a27caf4b113041fba96f153a41924e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763641800,
      "headline": "Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates",
      "id": 137556886,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug’s commercial potentialIn September 2025, Sol-Gel announced Health Canada approval of EPSOLAYSol-Gel signed an additional agreement with Viatris covering Australia and New Zealand for both EPSOLAY and TWYNEO NESS ZIONA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering t",
      "url": "https://finnhub.io/api/news?id=53c7343f10bdd7751e17ec1568e2f4274a27caf4b113041fba96f153a41924e0"
    }
  }
]